Authors
Katharina Röltgen, Abigail E Powell, Oliver F Wirz, Bryan A Stevens, Catherine A Hogan, Javaria Najeeb, Molly Hunter, Hannah Wang, Malaya K Sahoo, ChunHong Huang, Fumiko Yamamoto, Monali Manohar, Justin Manalac, Ana R Otrelo-Cardoso, Tho D Pham, Arjun Rustagi, Angela J Rogers, Nigam H Shah, Catherine A Blish, Jennifer R Cochran, Theodore S Jardetzky, James L Zehnder, Taia T Wang, Balasubramanian Narasimhan, Saurabh Gombar, Robert Tibshirani, Kari C Nadeau, Peter S Kim, Benjamin A Pinsky, Scott D Boyd
Publication date
2020/12/7
Journal
Science immunology
Volume
5
Issue
54
Pages
eabe0240
Publisher
American Association for the Advancement of Science
Description
SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, can neutralize the virus. It is, however, unknown which features of the serological response may affect clinical outcomes of COVID-19 patients. We analyzed 983 longitudinal plasma samples from 79 hospitalized COVID-19 patients and 175 SARS-CoV-2-infected outpatients and asymptomatic individuals. Within this cohort, 25 patients died of their illness. Higher ratios of IgG antibodies targeting S1 or RBD domains of spike compared to nucleocapsid antigen were seen in outpatients who had mild illness versus severely ill patients. Plasma antibody increases correlated with decreases in viral RNAemia, but antibody responses in acute illness were insufficient to predict inpatient outcomes. Pseudovirus neutralization assays and a scalable …
Scholar articles
K Röltgen, AE Powell, OF Wirz, BA Stevens, CA Hogan… - Science immunology, 2020
K Roltgen, AE Powell, OF Wirz, BA Stevens, CA Hogan… - 2020